[[p0te pharmaceuticals]]
Internal reference page — restricted circulation

Knuflium

1. Origin & Supply Context

Knuflium is a psychoactive compound of African origin. Its precise botanical and geographic provenance remains deliberately obscured; available information suggests circulation through non‑institutional research channels prior to its appearance in European experimental networks.

Persistent but unverified accounts indicate that early access within the Netherlands depended on a single intermediary with direct African supply ties. These accounts are anecdotal and should not be treated as actionable sourcing information.

Recent internal discussion suggests that limited local extraction or synthesis may be feasible, though this remains exploratory and insufficiently documented.

2. Observed Effects (Initial Phase)

Based on anecdotal reports, informal trials, and compassionate-use cases:

• Rapid onset of affiliative and prosocial behavior
• Marked reduction in social inhibition
• Increased tactile warmth and physical expressiveness
• Elevated trust toward perceived caregivers or formulators

Subjects often report these effects as comforting or stabilizing during early exposure. This framing may obscure secondary risks (see §4).

3. Behavioral Profile (Extended Exposure)

With repeated dosing or formulation escalation, additional patterns have been observed:

• Progressive erosion of emotional filtering
• Increased impulsive disclosure (emotional, verbal, decisional)
• Difficulty distinguishing authentic agency from chemically mediated trust

These effects are frequently misinterpreted as therapeutic openness or personal growth, particularly in socially anxious subjects.

4. Dependence, Withdrawal & Escalation Risk

• Abrupt discontinuation may result in acute psychological distress
• Subjects report anxiety, emotional volatility, and destabilization during gaps in availability
• Formulation adjustments can unintentionally amplify impulsivity

Because the compound is unapproved and not covered by insurance frameworks, continuity of supply is inherently fragile. This fragility itself appears to exacerbate dependence-related stress.

5. Formulation Notes

Knuflium is rarely administered in isolation. Adjustments to its proportion within a formulation have been made reactively, often under time pressure, based on subjective feedback.

While such adjustments may improve perceived efficacy, they also delay onset and obscure causal relationships between dose and behavioral outcome.

6. Internal Comment Log

(Auto-synced. Internal visibility. Not externally audited.)

• 26/01/2026 — A. Bakker: Routine check-in. No anomalies observed at baseline concentrations.
• 27/01/2026 — A. Bakker: Flagged need for clearer behavioral descriptors.
• 30/01/2026 — B. Clarke: Increased Knuflium proportion to improve onset and perceived efficacy. Monitoring advised.
• 02/02/2026 — A. Bakker: Concern regarding escalation without structural review. Recommend pause and reassessment.

Appendix A — Personal Lab Note (A. Bakker)

Not reviewed. Not circulated. Added during off-hours.

Subjects exhibit pronounced increases in honesty and impulse expression beyond socially adaptive levels. Decision-making shortcuts appear to bypass internal filtering entirely.

While initially framed as therapeutic openness, this loss of restraint may result in irreversible interpersonal damage. These effects are subtle, gradual, and therefore easy to misattribute.

Current summaries underestimate this risk.